SCHEMBL649784

SCHEMBL649784

CCCCc1c(C(=O)OCC)nn(C)c1-c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.50
CYP3A4 P08684 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP19A1 P11511 4/20 0.49
CA1 P00915 1/20 0.47
CA2 P00918 1/20 0.47
GRM5 P41594 1/20 0.47
TSHR P16473 4/20 0.46
NPSR1 Q6W5P4 3/20 0.46
MAPT P10636 3/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MAPK1 P28482 2/20 0.46
HSD17B10 Q99714 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
HTT P42858 1/20 0.46
CYP1A2 P05177 1/20 0.45
HPGD P15428 2/20 0.45
KMT2A Q03164 1/20 0.45
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27602286 0.90 GRM5 (0.50) ALDH1A1CYP3A4CYP2C9CYP2C19CA1
SCHEMBL10057637 0.83 ALDH1A1 (0.55) ALDH1A1CYP3A4CYP2C9CYP2C19CYP19A1
SCHEMBL1753231 0.81 ALDH1A1 (0.57) ALDH1A1CYP3A4CYP2C9CYP2C19CYP19A1
SCHEMBL1912785 0.80 CYP1A2 (0.50) ALDH1A1CYP3A4CYP2C9CYP2C19MAPT
SCHEMBL10172623 0.80 ALDH1A1 (0.52) ALDH1A1CYP3A4CYP2C9CYP2C19CYP19A1
SCHEMBL32691488 0.78 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP2C9CYP2C19CYP19A1
SCHEMBL9196652 0.78 ALDH1A1 (0.50) ALDH1A1CYP3A4CYP2C9CYP2C19CYP19A1
SCHEMBL23399565 0.77 HSD11B1 (0.47) ALDH1A1CYP2C9CYP2C19GRM5TSHR
SCHEMBL9204410 0.77 TSHR (0.51) ALDH1A1CYP3A4CYP2C9CYP2C19CYP19A1
SCHEMBL9204471 0.77 CYP19A1 (0.51) ALDH1A1CYP3A4CYP2C9CYP2C19CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2007-09-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490343-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2004-12-29 EP disclosed
US-20040116424-A1 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION 2004-06-17 US disclosed
WO-2003082829-A1 NEW ARYL IMIDAZOLES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070208048-A1 New Aryl Imidazoles and Related Compounds as C5a Receptor Modulators C3AR1, C5AR1, C5AR2 ALDH1A1 3370/4885CYP3A4 432/4885CYP2C9 595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.